Skip to Main Content

Paper Details

The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
Breast Cancer Research and Treatment
1
2022
21-gene recurrence score, CT, Cancer, HR, HR-positive/human epidermal growth factor receptor 2-negative breast cancer, NET, Patient, hormone receptor, hormone receptor-positive (HR-positive) breast cancer, human epidermal growth factor receptor 2, patients, progesterone, progesterone receptor
Author NameAffiliation
Anna WeissHarvard Medical School
Anna WeissDana-Farber Brigham Cancer Center
Anna WeissBrigham and Women's Hospital
Tari A KingHarvard Medical School
Tari A KingDana-Farber Brigham Cancer Center
Tari A KingBrigham and Women's Hospital
  • 1 - 6

Datasets

Release 1.2